Bulletin
Investor Alert

New York Markets Close in:

July 7, 2021, 11:33 p.m. EDT

Technology, Legislation, the Supreme Court, and Your Cannabis Portfolio (YCBD, ECOX, TLRY, GRWG)

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Eco Innovation Group Inc. (ECOX)
  • X
    Curaleaf Holdings Inc. (CURLF)

or Cancel Already have a watchlist? Log In

cbdMD Inc (nyseamerican:YCBD) promulgates itself as a company that produces and distributes various cannibidiol (CBD) products. It owns and operates the consumer hemp-based CBD brand, cbdMD. The company's product categories include CBD tinctures, capsules, gummies, bath bombs, topical creams, and animal treats and oils. It also offers pet related CBD products under the Paw CBD brand name.

The company distributes its products through an e-commerce Website, wholesalers, and various brick and mortar retailers in the United States.

cbdMD Inc (nyseamerican:YCBD) recently announced that its recently formed subsidiary, cbdMD Therapeutics, has begun a collaboration with researchers at the Colorado State University (CSU) veterinary program, to explore the effects of the Company's patent pending, proprietary cbdMD branded cannabinoid blend on dogs that suffer from osteoarthritis.

"It has been estimated that one in five dogs are diagnosed with osteoarthritis in their lifetime. With almost 1 billion dogs globally and over 75 million in the US, osteoarthritis effects millions of our loved ones. Paw CBD is committed to providing products that can improve our pet's quality of life and provide relief for joint discomfort for the millions of pets who suffer from this disease. Our partnership with CSU will serve as the foundation for future work where we will explore the clinical impact of our proprietary broad spectrum cannabinoid blend on pain and mobility in our pets," said Martin Sumichrast, Chairman and Co-CEO of cbdMD, Inc.

While this is a clear factor, it has been incorporated into a trading tape characterized by a pretty dominant offer, which hasn't been the type of action YCBD shareholders really want to see. In total, over the past five days, shares of the stock have dropped by roughly -6% on above average trading volume. All in all, not a particularly friendly tape, but one that may ultimately present some new opportunities. Over the past month, shares of the stock have suffered from clear selling pressure, dropping by roughly -14%.

cbdMD Inc (nyseamerican:YCBD) managed to rope in revenues totaling $11.8M in overall sales during the company's most recently reported quarterly financial data — a figure that represents a rate of top line growth of 25.5%, as compared to year-ago data in comparable terms. In addition, the company has a strong balance sheet, with cash levels exceeding current liabilities ($24.7M against $6.9M).

Curaleaf Holdings Inc /zigman2/quotes/205334348/composite CURLF +2.10% operates as a holding company with interest in medical and wellness cannabis operations. It operates through the Cannabis Operations and Non-Cannabis Operations segments. The Cannabis Operations segment includes the production and sale of cannabis via retail and wholesale channels.

The Non-Cannabis Operations segment provides professional services including cultivation, processing and retail know-how and back-office administration, intellectual property licensing, real estate leasing services and lending facilities to medical and adult-use cannabis licensees under management service agreements.

Curaleaf Holdings Inc /zigman2/quotes/205334348/composite CURLF +2.10% recently announced the opening of Curaleaf Edgewater Park, the Company's second dispensary in New Jersey and 107th dispensary nationwide. In addition, the Company announced that its second New Jersey cultivation facility, located in Winslow, completed its first harvest and is now fully operational. The new site has tripled Curaleaf's cultivation capabilities to serve both the existing New Jersey medical market and the forthcoming adult-use market.

"We are thrilled to grow alongside New Jersey's flourishing medical community and expand access to best-in-class cannabis products to patients in Edgewater Park," said Joe Bayern, CEO of Curaleaf. "We continue to work closely with state leadership and regulators to create a successful and sustainable adult-use market, and our expansion positions us to meet the market's increasing needs while creating hundreds of new jobs in the state."

The stock has suffered a bit of late, with shares of CURLF taking a hit in recent action, down about -4% over the past week. Over the past month, shares of the stock have suffered from clear selling pressure, dropping by roughly -6%.

Curaleaf Holdings Inc /zigman2/quotes/205334348/composite CURLF +2.10% managed to rope in revenues totaling $329.6M in overall sales during the company's most recently reported quarterly financial data — a figure that represents a rate of top line growth of 154%, as compared to year-ago data in comparable terms. In addition, the company has a strong balance sheet, with cash levels exceeding current liabilities ($395.4M against $299.1M).

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer . We may be compensated for posting this content on our website by EDM Media LLC. For questions, comments or suggestions please contact steve@edm.media.

The post Technology, Legislation, the Supreme Court, and Your Cannabis Portfolio (YCBD, ECOX, TLRY, GRWG) appeared first on Wall Street PR .

COMTEX_389497867/2770/2021-07-07T23:33:07

/zigman2/quotes/205334348/composite
US : U.S.: OTC
$ 8.75
+0.18 +2.10%
Volume: 438,999
Dec. 7, 2021 1:34p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$6.08 billion
Rev. per Employee
N/A
loading...
/zigman2/quotes/205334348/composite
US : U.S.: OTC
$ 8.75
+0.18 +2.10%
Volume: 438,999
Dec. 7, 2021 1:34p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$6.08 billion
Rev. per Employee
N/A
loading...
/zigman2/quotes/205334348/composite
US : U.S.: OTC
$ 8.75
+0.18 +2.10%
Volume: 438,999
Dec. 7, 2021 1:34p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$6.08 billion
Rev. per Employee
N/A
loading...

1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.